Thursday, Sept. 7, 2023 NIAID Scientists Develop Promising Vaccine for Kyasanur Forest Disease Virus Caption: Transmission electron micrograph showing vesicular stomatitis virus particles (orange) budding from infected cells (teal). NIAID With pathogen-carrying ticks expanding their territories in many parts of the world, a NIAID research group has likewise expanded its vaccine research to two typically rare pathogens with potential for public health importance. Few people have heard of Kyasanur Forest disease (KFD) or Alkhurma hemorrhagic fever (AHF), but the closely related viral diseases are, respectively, on the minds of people in India and Saudi Arabia. In a new study published in Science Advances, researchers describe how they used genetically engineered vesicular stomatitis virus (VSV) as the platform to develop a single-dose KFD vaccine that was safe and protective in mice and pigtail macaques, and is ready for clinical trials. They also showed that the same vaccine, known as VSV-KFDV, generated cross-neutralizing immune responses against AHF, results that need confirmation through efficacy testing in animal models. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107